托吡酯(Topiramate) - 药物靶点：AMPA receptor x CAs x GABAA receptor x VGSCs_在研适应症：癫痫，偏头痛，Lennox-Gastaut综合征_专利_临床

概要

基本信息

简介托吡酯以商品名Topamax ® 销售，是一种抗惊厥药物，于1995年在英国由Janssen Services 首次推上市场。其作用机制为 GABAAR 激动剂。主要用于治疗癫痫，也被批准用于预防和治疗偏头痛。托吡酯通过稳定大脑中的电活动起作用，从而降低癫痫发作的可能性。已发现它可有效降低癫痫患者癫痫发作的频率和严重程度，以及减少偏头痛的频率。托吡酯有片剂形式，通常按照医疗保健提供者的指示每天口服一次或两次。

药物类型

小分子化药

别名

2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate、2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate、Topiramate (JAN/USP/INN)

+ [22]

靶点

AMPA receptor x CAs x GABAA receptor x VGSCs

作用机制

AMPA receptor拮抗剂(离子型谷氨酸受体AMPA拮抗剂)、CAs抑制剂(碳酸酐酶家族抑制剂)、GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂)

治疗领域

神经系统疾病遗传病与畸形其他疾病

在研适应症

癫痫偏头痛Lennox-Gastaut综合征+ [4]

非在研适应症

精神病性情感障碍酗酒暴食症+ [24]

原研机构

Janssen Global Services LLC

在研机构

Upsher-Smith Laboratories LLC

Azurity Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

+ [6]

非在研机构

Janssen Pharmaceutica NVJohnson & Johnson Pharmaceutical Research & Development LLCOrtho-mcneil Neurologics, Inc.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1996-12-24),

癫痫部分性发作强直阵挛性癫痫

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C12H21NO8S

InChIKeyKJADKKWYZYXHBB-XBWDGYHZSA-N

CAS号97240-79-4

关联

325

项与托吡酯相关的临床试验

NCT05209984 / Not yet recruiting临床3期

A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/Obesity

A phase 3, multicenter, randomized, double-blind, double-dummy, parallel-group, active-drug- and placebo-controlled clinical trial to assess the safety, efficacy and superiority of the new fixed-dose combination sibutramine IR/topyramat XR in weight reduction in overweight adults with comorbidity(ies) or obesity

开始日期2025-10-30

申办/合作机构

Eurofarma Laboratórios SA

TCTR20240527003 / Not yet recruiting临床1期IIT

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Topiramate 100 mg tablets relative to Topamax 100 mg tablets, in healthy Thai volunteers under fasting condition

开始日期2025-02-11

申办/合作机构

Bio-innova Co., Ltd

CTRI/2024/11/076189 / Not yet recruiting临床2期IIT

A study of naltrexone and topiramate combination versus naltrexone alone in craving in alcohol dependence - NIL

开始日期2024-11-06

申办/合作机构-

100 项与托吡酯相关的临床结果

登录后查看更多信息

100 项与托吡酯相关的转化医学

登录后查看更多信息

100 项与托吡酯相关的专利（医药）

登录后查看更多信息

5,941

项与托吡酯相关的文献（医药）

2025-01-01·CLINICAL ENDOCRINOLOGY

Anti‐Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps

Review

作者: Kelly, Aaron S. ; Ells, Louisa J. ; Torbahn, Gabriel ; Lischka, Julia ; Wabitsch, Martin ; Brown, Tamara ; Weghuber, Daniel

ABSTRACT:

Background:

Paediatric obesity is a global public health concern. While in most countries the incidence keeps rising, the need for effective and long‐term management for children and adolescents living with this chronic, relapsing disease is pressing. Health behaviour and lifestyle treatment (HBLT) is recommended as first‐line treatment.

Methods:

Narrative review.

Results:

A new generation of recently approved anti‐obesity medications (AOM) now has the potential to fill the gap between limited effects on body mass index (BMI) by HBLT alone and large effects by metabolic and bariatric surgery in adolescents with obesity aged 12 years and older. While, for semaglutide and phentermine/topiramate, effectiveness is substantial with relevant, but mostly mild to moderate adverse events, there is a gap in evidence regarding long‐term effects and safety, effects on outcomes beyond BMI reduction and data for certain groups of patients, such as children < 12 years and minority groups. When integrating AOM treatment into national healthcare systems it should be offered as part of a comprehensive patient‐centred approach.

Conclusion:

This article summarizes recent AOM developments, integration into paediatric obesity management, and identifies research gaps.

2025-01-01·JOURNAL OF COMMUNICATION DISORDERS

Characterizing drug-induced stuttering in electronic health records

Article

作者: Pruett, Dillon G ; Shuey, Megan M ; Hunter, Christine ; Kraft, Shelly Jo ; Jones, Robin M ; Below, Jennifer E ; Shaw, Douglas M ; Scartozzi, Alyssa

PURPOSE:

Drug-induced stuttering is a phenomenon where the onset of stuttered speech is caused by exposure to pharmaceutical chemical substances. This acquired form of stuttering features many of the same overt speech behaviors as developmental stuttering. Investigations of drug-induced stuttering have been limited to adverse drug reaction reports and case studies. This study leveraged electronic health records (EHRs) at a major university medical center to identify drug-induced stuttering within medical notes, followed by classification of implicated drug types.

METHODS:

A previous systematic EHR review of approximately 3 million individuals to identify cases of developmental stuttering resulted in 40 suspected cases of drug-induced stuttering. In the present study, these cases were reviewed comprehensively to evaluate: name, class, and mechanism of action of suspected drug, level of evidence for the implicated drug as a causal agent, therapeutic measures taken, and progression or remission of stuttering.

RESULTS:

Eighteen different drugs were linked to possible drug-induced stuttering in 22 individuals. Antiseizure agents, CNS stimulants, and antidepressants were the most common drug classes implicated in drug-induced stuttering. topiramate (Topamax) was the most commonly implicated drug across all records reviewed.

CONCLUSIONS:

This study represents the first analysis of health system data examining drugs implicated in drug-induced stuttering in a clinical setting. Augmenting previous case reports and database reviews, a variety of drugs were identified; however, improved reporting of drug-associated speech fluency changes within the EHR are needed to further amass evidence for suspected drugs and their associated epidemiological and clinical characteristics.

2024-12-01·Pain and Therapy

Cerebral Artery Vasoconstriction After Galcanezumab Loading Dose for Migraine Prevention: A Case Report

Article

作者: Blumenfeld, Andrew ; Asawavichienjinda, Thanin ; Jittapiromsak, Nutchawan

Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies that target CGRP ligands or receptors, may cause a very rare side effect of reversible cerebral vasoconstriction syndrome (RCVS). This study is a case report of a patient who developed cerebral artery vasoconstriction documented on serial brain magnetic resonance angiography (MRA) scans without the typical manifestations of RCVS following galcanezumab loading dose. Case report: A 40-year-old female patient with high-frequency episodic migraine with visual aura on topiramate 100 mg/day developed transient numbness of the right upper and lower extremities and right face without headache and a normal neurological examination 10 min after a loading dose of galcanezumab, which resolved over the next 2 days. Magnetic resonance angiography brain imaging showed segmental arterial constriction of both middle cerebral arteries in the M1-2 segments and both posterior cerebral arteries in the P1-2 segments, which partial resolved in a subsequent study by the end of 6 months. There were no other supporting examination data, such as transcranial Doppler, which might provide additional information on the progression and improvement of the vasoconstriction. Her differential diagnosis included prolonged migraine sensory aura without headache, RCVS, or cerebral vasoconstriction secondary to the effect of an anti-CGRP monoclonal antibody. Further research needs to be conducted.

118

项与托吡酯相关的新闻（医药）

2024-12-06

·drugs

Many Women With Epilepsy Unaware of Seizure Meds' Risks to Pregnancy

FRIDAY, Dec. 6, 2024 -- Many women with epilepsy who are of childbearing age might not realize their anti-seizure drugs can raise the risk of birth defects or dampen the effectiveness of their birth control, a new study warns. Likewise, some birth control methods can cause anti-seizure meds to be less effective, researchers reported Friday in a presentation at the annual meeting of the American Epilepsy Society in Los Angeles. “Many neurologists do not learn about birth control in their training, even though they know that anti-seizure medications may have some risks in pregnancy,” said senior researcher Dr. Sarah Betstadt , an associate professor of obstetrics and gynecology at the University of Rochester Medical Center. “We hope this study raises awareness for patients and encourages health care providers from neurology and reproductive health care to work together to ensure the best care for these patients,” Betstadt added in a society news release. For the study, researchers surveyed 107 women ages 18 to 49 who were taking anti-seizure medications about their reproductive plans. Six said they were pregnant or planning to become pregnant, and another 69 said they were using some sort of birth control that could interfere with their anti-seizure meds, researchers said. The survey quizzed women on their knowledge regarding birth control and anti-seizure meds, and found that: “Survey participants may not have known that their answers were wrong and so did not feel they needed more information,” Betstadt noted. Only about a third of the women were receiving medical care that aligned with their reproductive plans, researchers found. Anti-seizure medications that increase the risk of birth defects include valproic acid , topiramate , carbamazepine , phenobarbital and phenytoin. Further, anti-seizure drugs that can make hormonal contraceptives like pills, patches and rings less effective include carbamazepine, phenytoin , phenobarbital, and higher doses of topiramate and oxcarbazepine . Despite that, no anti-seizure drug is as dangerous for an expecting mother or her fetus as uncontrolled seizures , the researchers noted. Women who want to become pregnant should talk with their doctor about drugs that are less risky but still can control their seizures, researchers said. “Neurology and reproductive health care providers should collaborate to provide the safest and most effective care for their patients of reproductive age who are taking anti-seizure medications,” Betstadt said. “This collaboration can help patients navigate their reproductive choices while minimizing drug-drug interactions that may reduce the effectiveness of seizure medications and/or birth control methods,” Betstadt added. Findings presented at medical meetings should be considered preliminary until they’re published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-11-28

·国际糖尿病idiabetes

体重管理新纪元：减重治疗药物研发多波折，GLP-1RA周制剂提供新变革！

点击“蓝字”关注我们编者按：肥胖医学协会将肥胖定义为一种严重的、慢性的、进行性的、复发性的、可治疗的多因素神经行为疾病，其中体内脂肪增加促进脂肪组织功能障碍和异常脂肪组织的压迫，导致不良的代谢、生物学和社会心理健康等后果。肥胖患者面临着发病率和死亡率增加的问题，同时在执行日常任务（如爬楼梯）时也受到限制。肥胖与220多种并发症有关，例如2型糖尿病（T2DM）、代谢功能障碍相关脂肪性肝病（MASLD）和慢性肾脏病（CKD），这些并发症也限制了患者的能力，亟需药物治疗[1]。过去多年，减重治疗药物研发历经诸多波折，胰高糖素样肽-1受体激动剂（GLP-1RA）的减重适应证获批为肥胖治疗提供了新变革！本刊邀请解放军总医院第一医学中心臧丽教授对减重药物的研发历史进行回顾，一起来看看！臧丽教授解放军总医院第一医学中心内分泌科副主任医师副教授硕士生导师中华医学会糖尿病学分会青年委员会副主任委员中国医师协会内分泌代谢科分会青年委员会副主任委员北京医学会糖尿病学分会委员兼工作秘书解放军医学会内分泌学分会青年委员会秘书长国际糖尿病杂志青年编委《Diabetes Care 中文版》青年编委《Endocrine Reviews 中文版》青年编委肥胖症的药物治疗有着悠久而曲折的历史，早在19世纪末，西方就已出现用药物治疗肥胖的方法，如甲状腺激素类药物等。在随后100多年，线粒体解偶联剂、肾上腺素能药物等逐渐进入市场。但可惜好景不长，许多有前景的药物因各种问题而被陆续撤回（图1）[2-4]。图1. 目前FDA批准的减重药物预览究其根本，安全性是导致减重药物撤市的重要原因。其中，大多数药物（如西布曲明、芬氟拉明、右芬氟拉明、彩虹药丸）与心血管不良影响相关，而部分药物（如利莫那班）可能导致自杀风险增加，部分药物（如甲基苯丙胺）会导致药物依赖和滥用的可能性增加。此外，由于成瘾潜力或出现快速耐受，某些药物仅建议短期使用（芬特明、安非拉酮、盐酸卡汀）[2-4]。上市减重药物选择有限，研发面临多重挑战由于技术和社会原因，寻求抗肥胖药物一直极具挑战性。目前，经美国食品药品监督管理局（FDA）批准用于抗肥胖的药物有脂肪酶抑制剂的奥利司他、去甲肾上腺素（NE）激动剂/γ-氨基丁酸（GABA）激动剂和谷氨酸拮抗剂的芬特明/托吡酯组合、阿片受体拮抗剂/多巴胺（DA）和NE再摄取抑制剂的纳曲酮/安非他酮组合、GLP-1RA的利拉鲁肽和司美格鲁肽以及GIP/GLP-1双靶点激动剂的替尔泊肽（图2）[2-4]，而我国批准的药物仅有奥利司他、贝那鲁肽0.2 mg、司美格鲁肽2.4 mg、利拉鲁肽3.0 mg这4种药物[2-4]。图2. FDA批准的治疗肥胖症的药物及其作用部位其中，奥利司他作为脂肪酶抑制剂可通过抑制胃肠道和胰腺脂肪酶，从而阻断甘油三酯的水解并减少肠内皮对脂肪酸的吸收。研究发现，其通常会导致与食物一起消耗的大约1/3的脂肪酸不被吸收[2]。XENDOS研究发现，奥利司他组体重减轻为5.8 kg，服用奥利司他后不良反应主要为便秘、腹痛、腹泻、头晕、月经紊乱和皮疹等，长期应用可能导致脂溶性维生素如维生素D、维生素E、维生素K等缺乏[5]。 GLP-1RA占据主导地位，引领减重新变革实现体重正常化以及适当的耐受能力和安全性的长期药物治疗仍然是一个难以克服的挑战。然而，最近针对包括GLP-1RA在内的先进治疗候选药物的临床试验使大家相信，突破性的、基于药物的肥胖管理有可能实现。2014年，FDA批准利拉鲁肽3 mg用于治疗成人肥胖，成为首个用于体重管理的GLP-1RA[2-4]。今年，FDA批准司美格鲁肽2.4 mg用于初始体重指数（BMI）≥30 kg/m2（肥胖）或≥27 kg/m2至<30 kg/m2（超重）且存在至少1种体重相关合并症，如高血糖、高血压、血脂异常、阻塞性睡眠呼吸暂停或心血管疾病等患者，成为首个用于体重管理的GLP-1RA周制剂。究其原因，GLP-1RA一方面可延缓胃排空和胃肠蠕动，增加机体饱腹感，降低摄食；同时增加能量消耗，促进内脏白色脂肪向棕色脂肪转化，随着棕色脂肪产热增加，增加能量耗损；另一方面，GLP-1RA可直接刺激阿黑皮素原（POMC）/可卡因苯丙胺调节转录物（CART）阳性神经元，并通过GABA信号间接抑制神经肽Y（NPY）和刺鼠相关肽（AgRP）阳性神经元的神经投射，从而抑制食欲，减少摄食量[2-4]。 STEP系列研究证实了司美格鲁肽2.4 mg每周一次皮下注射与安慰剂相比的疗效和安全性。其结果显示，司美格鲁肽2.4 mg组治疗68周后，显著降低体重达15%~17%（图3）[6-11]。图3. 司美格鲁肽2.4 mg显著降低体重司美格鲁肽2.4 mg的安全性也经过了验证，不良事件发生率与安慰剂组相仿，导致停药的不良事件发生率低，通常为轻中度、一过性的胃肠道反应，如恶心、腹泻、呕吐和便秘等，并随治疗时间延长而逐渐减轻或消失[6-11]。纳入STEP 1、2、3和5研究的事后分析发现，68周时，与安慰剂相比，司美格鲁肽2.4 mg治疗不仅不会增加出现抑郁或自杀意念/行为症状的风险，而且可能与抑郁症状的小幅减少相关。结语药物研发过程漫长而艰辛，许多药物因各种原因退市，不能成为临床用药。尽管如此，临床肥胖患者需求和巨大市场仍是持续进行抗肥胖药物研发的强大动力。随着GLP-1RA减重适应证的批准上市，肥胖治疗出现了新变革。相信未来随着新兴生物医学工程技术的发展以及个性化多分子药物的开发，肥胖治疗会更安全、更持久、更有效，不仅能更好地减轻体重，还能改善心脏代谢健康，为肥胖症的精准医疗开辟新径。注：不同剂量的司美格鲁肽注射液用于不同的适应证，本材料所提及的司美格鲁肽（2.4 mg）注射液的适应证均为适用于长期体重管理治疗的GLP-1RA周制剂。其具体适应证为：适用于在控制饮食和增加体力活动的基础上对成人患者的长期体重管理，初始体重指数（BMI）符合以下条件：≥30 kg/m2（肥胖），或≥27 kg/m2至<30 kg/m2（超重）且存在至少1种体重相关合并症，例如高血糖、高血压、血脂异常、阻塞性睡眠呼吸暂停或心血管疾病等。参考文献（上下滑动可查看） 1.Craig HC, et al. Obes Pillars. 2024 Aug 8; 12: 100123. 2.Pilitsi E, et al. Metabolism. 2019; 92: 170-192. 3.Müller TD, et al. Nat Rev Drug Discov. 2022; 21(3): 201-223. 4.Onakpoya IJ, et al. BMC Med. 2016; 14(1): 191. 5.Ludvik B, et al.Diabetes Care. 2004; 27(2): 436-440. 6.Wilding JPH, et al. N Engl J Med. 2021; 384(11): 989-1002. 7.Davies M, et al. Lancet. 2021; 397(10278): 971-984. 8.Wadden TA, et al. JAMA. 2021; 325(14): 1403-1413. 9.Rubino D, et al. JAMA. 2021; 325(14): 1414-1425. 10.Garvey WT, et al. Nat Med. 2022; 28(10): 2083-2091. 11.Kadowaki T, et al. Lancet Diabetes Endocrinol. 2022; 10(3): 193-206. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

2024-11-27

·奇点网

妊娠期用药要注意！

*仅供医学专业人士阅读参考抗癫痫药物是精神疾病患者控制病情稳定的重要管理方式。但是，由于孕期情况复杂，药物使用受到需要限制，某些抗癫痫药物（比如丙戊酸）是公认的致畸剂，同时，越来越多的证据表明一些抗癫痫药物与胎儿畸形和后代长期神经发育障碍有关，提示了丙戊酸之外其他抗癫痫药物的潜在风险。来自布里斯托大学的研究人员讨论了其他抗癫痫药物在妊娠期间长期安全性证据。结果显示，与孕期未接触过抗癫痫药物的儿童相比，接触过丙戊酸的儿童更有可能患自闭症、智力障碍和注意缺陷多动障碍（ADHD）。此外，托吡酯与儿童患智力障碍风险增加148%有关，卡马西平与儿童自闭症风险增加25%有关，与儿童智力障碍风险增加30%有关。研究发表在《自然·通讯》杂志上。研究数据来自英国CPRD GOLD的初级保健数据和瑞典健康和疾病发展起源（DOHaD）队列，主要暴露是胎儿在怀孕期间接触抗癫痫药物单药或多药治疗，主要结果为自闭症、智力障碍和ADHD，混杂因素包括母亲特征、母亲神经发育状况等。最终的分析队列包括英国的518047名活产儿童和瑞典的2664726名活产儿童。在3182773名儿童中，有17495名接触过抗癫痫药物，78442名儿童诊断有自闭症，26787名被诊断有智力障碍，155329名诊断有ADHD。调整混杂因素进行分析，未接触过抗癫痫药物儿童12岁时患自闭症、智力障碍和ADHD的预期绝对风险分别为3.01%、0.92%和2.50%。对于接触过抗癫痫药物的儿童来说，不同药物的神经发育障碍的绝对风险不同。丙戊酸单药治疗的儿童，三种神经发育障碍的预期绝对风险都最高，分别为4.85%、2.36%和6.34%。除此之外，加巴喷丁单药治疗的儿童自闭症预期绝对风险为3.67%，托吡酯单药治疗的儿童智力障碍预期绝对风险为2.14%，苯妥英单药治疗的儿童ADHD预期绝对风险为6.30%。与未接触抗癫痫药物的儿童相比，丙戊酸与自闭症风险增加78%有关，与智力障碍风险增加156%有关，与ADHD风险增加20%有关；卡马西平与自闭症风险增加25%有关、与智力障碍风险增加30%有关；托吡酯与智力障碍风险增加148%有关；多药治疗与自闭症风险增加51%有关、与智力障碍风险增加102%有关。总的来说，这项大规模研究支持先前的研究结果，孕期使用丙戊酸，或其他抗癫痫药物，托吡酯、卡马西平，与后代的神经发育疾病有关。几乎没有证据表明孕期接触拉莫三嗪会增加神经发育疾病的风险。研究作者表示，“对任何抗癫痫药物都应该进行积极监测，确保安全性和有效性，尤其是在怀孕期间，应根据患者的具体情况作出相应决定”。参考文献：Madley-Dowd P, Ahlqvist VH, Forbes H, et al. Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun. 2024;15(1):9640. Published 2024 Nov 15. doi:10.1038/s41467-024-53813-1本文作者丨王雪宁

孤儿药临床结果

100 项与托吡酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00537	托吡酯	N03AX11	DB00273

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
癫痫	日本	Kyowa Kirin Co., Ltd.	2007-07-31
偏头痛	美国	Janssen Pharmaceuticals, Inc.	2004-08-11
Lennox-Gastaut综合征	美国	Janssen Pharmaceuticals, Inc.	2001-08-28
癫痫部分性发作	美国	Janssen Pharmaceuticals, Inc.	1996-12-24
强直阵挛性癫痫	美国	Janssen Pharmaceuticals, Inc.	1996-12-24

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
病理性赌博症	临床3期	美国	Ortho-McNeil Pharmaceutical LLC	2005-10-01
尼古丁成瘾	临床3期	美国	Ortho-mcneil Neurologics, Inc.	2005-09-22
暴食症	临床3期	-	Janssen-Cilag Farmacêutica Ltda.	2003-11-01
强迫症	临床3期	美国	Ortho-McNeil Pharmaceutical LLC	2003-01-01
创伤后应激障碍	临床3期	美国	Ortho-mcneil Neurologics, Inc.	2002-09-01
神经认知障碍	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2002-01-01
躁郁症	临床3期	-	Ortho-mcneil Neurologics, Inc.	2001-10-01
特发性震颤	临床3期	-	Ortho-mcneil Neurologics, Inc.	2001-10-01
特发性震颤	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2001-10-01
震颤	临床3期	-	Ortho-mcneil Neurologics, Inc.	2001-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01765218 (CTgov)	临床1/2期	缺氧缺血性脑病	34	Placebo (Placebo)	廠壓鬱網積廠艱顧艱遞(鹹壓糧選窪製醖積衊簾) = 鏇鹽淵顧網醖獵繭齋選夢鹽蓋鹽窪淵淵齋糧遞 (顧窪衊鹹簾鬱簾淵壓鹹, 膚餘廠壓鏇願顧構蓋廠 ~ 製醖選製襯壓膚範淵積) 更多	-	2024-06-11
				Topiramate (Topiramate)	廠壓鬱網積廠艱顧艱遞(鹹壓糧選窪製醖積衊簾) = 觸簾顧齋顧簾鬱繭築鹽夢鹽蓋鹽窪淵淵齋糧遞 (顧窪衊鹹簾鬱簾淵壓鹹, 餘餘鏇餘淵鬱壓鑰積選 ~ 願廠蓋構艱獵構願壓糧) 更多
NCT00606411 (CTgov)	早期临床1期	-	34	Topiramate or Placebo (Topiramate)	餘觸齋鑰築鑰遞淵鏇顧(觸糧築網蓋鹹淵廠獵範) = 艱網衊蓋艱鏇夢鹽襯遞淵遞鑰選鑰憲願廠遞膚 (廠壓醖製蓋齋積壓範艱, 憲鹹夢簾壓鹽積願鏇壓 ~ 選鹹顧衊夢構襯鏇膚壓) 更多	-	2024-04-19
				Topiramate or Placebo (Placebo)	餘觸齋鑰築鑰遞淵鏇顧(觸糧築網蓋鹹淵廠獵範) = 壓衊糧糧範簾艱製憲構淵遞鑰選鑰憲願廠遞膚 (廠壓醖製蓋齋積壓範艱, 簾夢遞積積鑰製衊廠衊 ~ 構膚衊鑰餘衊憲壓窪蓋) 更多
APAO2024	N/A	闭角型青光眼	4	Topiramate	築鏇憲蓋築艱醖構衊鏇(淵衊繭鏇範鹹憲積鹹顧) = All four cases had a history of intake of topiramate within the past 2-3 weeks prescribed by their physicians for the symptom of headache 鏇艱鹹壓觸憲鹹遞繭構 (觸廠積襯鏇襯繭壓選網 )	积极	2024-02-22
APAO2024	N/A	-	-	Topiramate	憲夢觸衊鹽醖構夢壓醖(壓鬱鏇範膚膚衊鑰餘膚) = Bilateral shallow Anterior chamber (AC) 齋繭構簾觸鑰窪淵獵網 (窪鑰壓鹽餘餘築繭築選 ) 更多	-	2024-02-22
NCT03176953 (TOP, CTgov)	临床2/3期	酒精使用障碍 \| 创伤后应激障碍	100	prolonged exposure+topiramate (Prolonged Exposure + Topiramate)	積艱廠構蓋襯餘鏇顧醖(網衊築鏇衊憲遞鹹選醖) = 蓋廠夢餘鹹獵構鏇鏇觸網範壓醖窪鹽憲繭構築 (憲網艱簾簾齋壓觸窪築, 製顧選顧繭積餘憲窪襯 ~ 鏇築簾齋範鏇糧獵醖積) 更多	-	2023-11-18
				placebo (Prolonged Exposure + Placebo)	積艱廠構蓋襯餘鏇顧醖(網衊築鏇衊憲遞鹹選醖) = 築醖願願鑰選艱觸壓齋網範壓醖窪鹽憲繭構築 (憲網艱簾簾齋壓觸窪築, 艱廠壓製獵積積醖選憲 ~ 夢選襯鏇築蓋顧鬱鏇夢) 更多
NCT02878798 (TopCSPN, CTgov)	临床2期	代谢综合征	132	Placebo (Placebo)	齋顧糧膚壓窪壓鬱鏇鹽(築構憲獵鬱醖鏇鹹範壓) = 齋夢艱壓廠艱獵鏇網範製鹹鑰憲鑰齋範窪壓鹹 (糧構繭襯壓糧遞醖淵壓, 壓艱淵壓網糧壓選夢簾 ~ 獵遞壓願衊構獵繭範醖) 更多	-	2023-11-14
				topiramate (Topiramate)	齋顧糧膚壓窪壓鬱鏇鹽(築構憲獵鬱醖鏇鹹範壓) = 憲選鹹壓製窪鏇壓遞餘製鹹鑰憲鑰齋範窪壓鹹 (糧構繭襯壓糧遞醖淵壓, 鹹範觸選願選觸願選範 ~ 製網衊鹽蓋壓憲範獵鏇) 更多
NCT00208130 (25(5):23m03555, Pubmed)	临床4期	创伤后应激障碍	72	Topiramate	憲觸廠繭網壓遞簾繭網(膚廠遞淵憲遞簾網蓋壓) = 26% vs 18% 糧糧選壓遞襯艱壓鹽築 (選憲繭糧鹽蓋觸選製網 ) 更多	积极	2023-10-19
				Placebo
IEC2023	N/A	-	-	Topiramate 200 mg/day	顧觸積憲憲選鏇憲襯遞(遞鹽鹹製選餘廠廠選選) = 憲廠廠積鏇繭憲製製獵蓋膚觸觸遞糧艱鹹齋餘 (鬱範襯淵餘繭廠餘憲憲 )	-	2023-09-04
				Valproic acid	醖積壓廠艱壓淵廠壓網(遞憲糧蓋網製鏇夢艱鬱) = 獵糧鑰鏇鏇膚衊鹽遞窪獵糧願築願鏇壓製壓糧 (鑰艱鏇膚淵齋衊簾願積 ) 更多
EURAP registry (IEC2023)	N/A	先天性畸形	9,840	Valproate	觸襯壓積構鏇膚範繭廠(齋憲觸壓夢觸鹹鑰積齋) = 糧齋淵壓淵遞壓構醖鹹築艱壓顧衊憲窪積積夢 (憲蓋窪顧壓餘淵顧繭艱 )	积极	2023-09-04
				Phenytoin	觸襯壓積構鏇膚範繭廠(齋憲觸壓夢觸鹹鑰積齋) = 鬱鏇觸鑰齋壓鏇廠淵繭築艱壓顧衊憲窪積積夢 (憲蓋窪顧壓餘淵顧繭艱 )
ANA2023	N/A	癫痫发作	396	Topiramate monotherapy	齋鏇製蓋夢糧齋繭繭艱(蓋壓鹹鹹觸積憲範積襯) = 範醖構壓鬱範齋選糧憲選壓構廠醖簾蓋獵鹹蓋 (鬱壓餘範衊顧窪窪網醖, 117.7) 更多	积极	2023-09-01
				Topiramate polypharmacy	艱觸簾壓鏇廠繭築夢鹽(願膚築艱遞繭淵鏇選醖) = 選選憲簾選襯觸糧窪壓憲網獵鬱齋鏇簾積齋網 (夢範製廠廠繭蓋遞鏇網, 1.1)